MedPath

ALEXION PHARMACEUTICALS, INC.

ALEXION PHARMACEUTICALS, INC. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
1992-01-01
Employees
3.8K
Market Cap
-
Website
http://www.alexion.com

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

Phase 3
Recruiting
Conditions
Paroxysmal Nocturnal Hemoglobinuria
PNH
Extravascular Hemolysis
Interventions
First Posted Date
2024-06-07
Last Posted Date
2025-07-01
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
6
Registration Number
NCT06449001
Locations
🇬🇧

Research Site, Leeds, United Kingdom

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Recruiting
Conditions
Ultomiris-exposed Pregnant/ Postpartum
Pregnancy
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Atypical Hemolytic Uremic Syndrome (aHUS)
Generalized Myasthenia Gravis (gMG)
Neuromyelitis Optica Spectrum Disorder (NMOSD)
First Posted Date
2024-03-15
Last Posted Date
2025-01-07
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
75
Registration Number
NCT06312644
Locations
🇺🇸

North American call center (NACC), Boston, Massachusetts, United States

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Phase 3
Recruiting
Conditions
Immunoglobulin A Nephropathy
IgAN
Interventions
Drug: Placebo
First Posted Date
2024-03-04
Last Posted Date
2025-07-01
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
510
Registration Number
NCT06291376
Locations
🇬🇧

Research Site, Stevenage, United Kingdom

A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy Adult Participants
Interventions
Drug: Gefurulimab AI
First Posted Date
2024-01-17
Last Posted Date
2024-10-23
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
175
Registration Number
NCT06208488
Locations
🇨🇦

Research Site, Laval, Quebec, Canada

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

Phase 3
Active, not recruiting
Conditions
Transthyretin Amyloid Cardiomyopathy
Interventions
Drug: Placebo
First Posted Date
2023-12-28
Last Posted Date
2025-07-01
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
1158
Registration Number
NCT06183931
Locations
🇬🇧

Research Site, Manchester, United Kingdom

A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults

First Posted Date
2023-12-15
Last Posted Date
2024-06-20
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
60
Registration Number
NCT06173596
Locations
🇬🇧

Research Site, Ruddington, United Kingdom

A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2023-12-07
Last Posted Date
2025-04-24
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
20
Registration Number
NCT06160414
Locations
🇬🇧

Research Site, Ruddington, United Kingdom

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

Phase 3
Recruiting
Conditions
Hypophosphatasia
Interventions
Drug: Placebo
First Posted Date
2023-10-12
Last Posted Date
2025-06-18
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
30
Registration Number
NCT06079359
Locations
🇻🇳

Research Site, Hanoi, Vietnam

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

Phase 3
Active, not recruiting
Conditions
Hypophosphatasia
Interventions
First Posted Date
2023-10-12
Last Posted Date
2025-03-18
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
42
Registration Number
NCT06079372
Locations
🇬🇧

Research Site, Sheffield, United Kingdom

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

Phase 3
Active, not recruiting
Conditions
Hypophosphatasia
Interventions
Drug: Placebo
First Posted Date
2023-10-12
Last Posted Date
2025-07-02
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
124
Registration Number
NCT06079281
Locations
🇬🇧

Research Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath